You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNicardipine
Accession NumberDB00622  (APRD00088)
TypeSmall Molecule
GroupsApproved
DescriptionA potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [PubChem]
Structure
Thumb
Synonyms
Cardene
Nicardipino
Nicardipinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cardene 20mg Capsulescapsule20 mgoralHoffmann La Roche Limited1996-12-312001-07-19Canada
Cardene 30mg Capsulescapsule30 mgoralHoffmann La Roche Limited1998-01-212001-07-19Canada
Cardene Cap 30mgcapsule30 mgoralSyntex Inc.1990-12-311998-09-03Canada
Cardene I.V.injection2.5 mg/mLintravenousEkr Therapeutics1992-01-30Not applicableUs
Cardene I.V.injection, solution.2 mg/mLintravenousEKR Therapeutics, Inc.1992-01-30Not applicableUs
Cardene I.V.injection, solution.1 mg/mLintravenousEKR Therapeutics, Inc.1992-01-30Not applicableUs
Cardene I.V.injection, solution.1 mg/mLintravenousEKR Therapeutics, Inc.1992-01-30Not applicableUs
Cardene I.V.injection, solution.2 mg/mLintravenousEKR Therapeutics, Inc.1992-01-30Not applicableUs
Cardene IVinjection, solution.1 mg/mLintravenousChiesi USA, Inc.1992-01-30Not applicableUs
Cardene IVinjection, solution.2 mg/mLintravenousChiesi USA, Inc.1992-01-30Not applicableUs
Cardene IVinjection, solution.2 mg/mLintravenousChiesi USA, Inc.1992-01-30Not applicableUs
Cardene IVinjection, solution.1 mg/mLintravenousChiesi USA, Inc.1992-01-30Not applicableUs
Cardene SRcapsule, extended release30 mg/1oralCarilion Materials Management1992-02-21Not applicableUs
Nicardipine Hydrochlorideinjection2.5 mg/mLintravenousWest Ward Pharmaceuticals Corp2012-03-02Not applicableUs
Nicardipine Hydrochlorideinjection2.5 mg/mLintravenousWest Ward Pharmaceuticals Corp2012-03-02Not applicableUs
Nicardipine Hydrochlorideinjection2.5 mg/mLintravenousSun Pharma Global Inc.2009-11-17Not applicableUs
Nicardipine Hydrochlorideinjection25 mg/10mLintravenousWest Ward Pharmaceuticals Corp2012-03-02Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nicardipine Hydrochloridecapsule20 mg/1oralAv Kare, Inc.2010-05-05Not applicableUs
Nicardipine Hydrochloridecapsule30 mg/1oralCarilion Materials Management1996-07-19Not applicableUs
Nicardipine Hydrochloridecapsule20 mg/1oralMylan Pharmaceuticals Inc.1996-07-19Not applicableUs
Nicardipine Hydrochlorideinjection2.5 mg/mLintravenousWockhardt Limited2009-11-09Not applicableUs
Nicardipine Hydrochlorideinjection2.5 mg/mLintravenousSandoz Inc.2010-09-27Not applicableUs
Nicardipine Hydrochloridecapsule30 mg/1oralAv Kare, Inc.2010-05-05Not applicableUs
Nicardipine Hydrochloridecapsule30 mg/1oralAvera Mc Kennan Hospital2015-07-16Not applicableUs
Nicardipine Hydrochloridecapsule30 mg/1oralMylan Pharmaceuticals Inc.1996-07-19Not applicableUs
Nicardipine Hydrochlorideinjection2.5 mg/mLintravenousWockhardt USA LLC.2009-11-09Not applicableUs
Nicardipine Hydrochlorideinjection2.5 mg/mLintravenousEmcure Pharmaceuticals Ltd.2009-11-17Not applicableUs
Nicardipine Hydrochloridecapsule20 mg/1oralEpic Pharma, LLC2010-05-05Not applicableUs
Nicardipine Hydrochlorideinjection, solution2.5 mg/mLintravenousAmerican Regent, Inc.2009-11-17Not applicableUs
Nicardipine Hydrochlorideinjection, solution2.5 mg/mLintravenousMylan Institutional LLC2011-12-23Not applicableUs
Nicardipine Hydrochlorideinjection, solution2.5 mg/mLintravenousPharma Force, Inc.2009-11-17Not applicableUs
Nicardipine Hydrochloridecapsule30 mg/1oralEpic Pharma, LLC2010-05-05Not applicableUs
Nicardipine Hydrochlorideinjection2.5 mg/mLintravenousSandoz Inc.2009-11-17Not applicableUs
Nicardipine Hydrochloridecapsule20 mg/1oralCarilion Materials Management1996-07-19Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CardeneRoche
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Nicardipine Hydrochloride
Thumb
  • InChI Key: AIKVCUNQWYTVTO-UHFFFAOYNA-N
  • Monoisotopic Mass: 515.182313414
  • Average Mass: 515.986
DBSALT000499
Categories
UNIICZ5312222S
CAS number55985-32-5
WeightAverage: 479.525
Monoisotopic: 479.205635675
Chemical FormulaC26H29N3O6
InChI KeyInChIKey=ZBBHBTPTTSWHBA-UHFFFAOYSA-N
InChI
InChI=1S/C26H29N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15,24,27H,13-14,16H2,1-4H3
IUPAC Name
3-{2-[benzyl(methyl)amino]ethyl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassHydropyridines
Direct ParentDihydropyridinecarboxylic acids and derivatives
Alternative Parents
Substituents
  • Nitrobenzene
  • Dihydropyridinecarboxylic acid derivative
  • Phenylmethylamine
  • Benzylamine
  • Aralkylamine
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Vinylogous amide
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Methyl ester
  • Organic nitro compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Organic nitrite
  • C-nitro compound
  • Carboxylic acid ester
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Enamine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic zwitterion
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed for the management of patients with chronic stable angina and for the treatment of hypertension.
PharmacodynamicsNicardipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Nicardipine is similar to other peripheral vasodilators. Nicardipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Mechanism of actionBy deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, nicardipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Related Articles
AbsorptionWhile nicardipine is completely absorbed, it is subject to saturable first pass metabolism and the systemic bioavailability is about 35% following a 30 mg oral dose at steady state.
Volume of distribution
  • 8.3 L/kg
Protein binding>95%
Metabolism

Nicardipine HCl is metabolized extensively by the liver.

Route of eliminationNicardipine has been shown to be rapidly and extensively metabolized by the liver.
Half life8.6 hours
Clearance
  • 0.4 L/hr∙kg [Following infusion]
ToxicityOral LD50 Rat = 184 mg/kg, Oral LD50 Mouse = 322 mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.932
Blood Brain Barrier-0.9549
Caco-2 permeable-0.83
P-glycoprotein substrateSubstrate0.8581
P-glycoprotein inhibitor IInhibitor0.9036
P-glycoprotein inhibitor IIInhibitor0.8253
Renal organic cation transporterNon-inhibitor0.7502
CYP450 2C9 substrateNon-substrate0.8296
CYP450 2D6 substrateNon-substrate0.5554
CYP450 3A4 substrateSubstrate0.7228
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8558
Ames testNon AMES toxic0.562
CarcinogenicityNon-carcinogens0.7262
BiodegradationNot ready biodegradable0.9604
Rat acute toxicity2.9030 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.7332
hERG inhibition (predictor II)Non-inhibitor0.7316
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Ekr therapeutics inc
  • Amneal pharmaceutical
  • Barr laboratories inc
  • Mylan pharmaceuticals inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Bedford laboratories div ben venue laboratories inc
  • Bioniche pharma usa llc
  • Exela pharma sciences
  • Navinta llc
  • Pharmaforce inc
  • Sun pharma global inc
  • Wockhardt ltd
Packagers
Dosage forms
FormRouteStrength
Capsuleoral20 mg
Capsuleoral30 mg
Injection, solutionintravenous.1 mg/mL
Injection, solutionintravenous.2 mg/mL
Capsule, extended releaseoral30 mg/1
Capsuleoral20 mg/1
Capsuleoral30 mg/1
Injectionintravenous2.5 mg/mL
Injectionintravenous25 mg/10mL
Injection, solutionintravenous2.5 mg/mL
Prices
Unit descriptionCostUnit
Cardene SR 60 60 mg 12 Hour Capsule Bottle142.91USD bottle
Nicardipine 25 mg/10 ml ampule25.01USD ml
Nicardipine 25 mg/10 ml vial10.42USD ml
Cardene SR 45 mg 12 Hour Capsule3.22USD capsule
Cardene sr 45 mg capsule2.9USD capsule
Cardene sr 60 mg capsule sa2.29USD capsule
Cardene SR 30 mg 12 Hour Capsule2.02USD capsule
Cardene sr 45 mg capsule sa1.91USD capsule
Cardene-dex 40 mg/200 ml iv1.35USD ml
Cardene-nacl 40 mg/200 ml iv1.35USD ml
Cardene 30 mg capsule1.28USD capsule
Cardene sr 30 mg capsule sa1.21USD capsule
Cardene sr 30 mg capsule0.87USD capsule
Cardene 20 mg capsule0.8USD capsule
NiCARdipine HCl 30 mg capsule0.68USD capsule
Cardene-dex 20 mg/200 ml soln0.67USD ml
Cardene-nacl 20 mg/200 ml soln0.67USD ml
Nicardipine 30 mg capsule0.66USD capsule
NiCARdipine HCl 20 mg capsule0.48USD capsule
Nicardipine 20 mg capsule0.46USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5164405 No1992-11-172009-11-17Us
US7612102 No2007-12-262027-12-26Us
US7659291 No2007-04-182027-04-18Us
US8455524 No2007-04-182027-04-18Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point136-138 °CPhysProp
water solubility2.2 mg/LNot Available
logP3.82SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.00247 mg/mLALOGPS
logP4.34ALOGPS
logP3.56ChemAxon
logS-5.3ALOGPS
pKa (Strongest Basic)8.18ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area113.69 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity134.8 m3·mol-1ChemAxon
Polarizability49.95 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Takashi Sonobe, Hiroitsu Kawata, Masayoshi Aruga, Tadayoshi Ohmura, Satoru Yoneya, Chiharu Yamada, Yukio Kubota, “Composition for long acting nicardipine preparation and process of producing the composition.” U.S. Patent US4758437, issued March, 1979.

US4758437
General ReferencesNot Available
External Links
ATC CodesC08CA04
AHFS Codes
  • 24:28.08
PDB EntriesNot Available
FDA labelDownload (1.26 MB)
MSDSDownload (106 KB)
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Nicardipine.
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Nicardipine.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Nicardipine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Nicardipine.
AbirateroneThe serum concentration of Nicardipine can be increased when it is combined with Abiraterone.
AcebutololNicardipine may increase the hypotensive activities of Acebutolol.
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Nicardipine.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Nicardipine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Nicardipine.
AcetazolamideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Acetazolamide.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Nicardipine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Nicardipine.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Nicardipine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Nicardipine.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Nicardipine.
AlbendazoleThe serum concentration of Nicardipine can be increased when it is combined with Albendazole.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nicardipine.
AldosteroneThe serum concentration of Nicardipine can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Nicardipine.
AlectinibThe serum concentration of Nicardipine can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Nicardipine can be increased when it is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the hypotensive activities of Nicardipine.
AliskirenNicardipine may increase the hypotensive activities of Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Nicardipine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Nicardipine.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Nicardipine.
AlosetronThe metabolism of Alosetron can be decreased when combined with Nicardipine.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Nicardipine.
AlprenololNicardipine may increase the hypotensive activities of Alprenolol.
AmantadineThe serum concentration of Nicardipine can be increased when it is combined with Amantadine.
AmbrisentanNicardipine may increase the hypotensive activities of Ambrisentan.
AmifostineNicardipine may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Nicardipine.
Aminohippuric acidThe serum concentration of Nicardipine can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Nicardipine.
AmiodaroneThe serum concentration of Nicardipine can be decreased when it is combined with Amiodarone.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Nicardipine.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Nicardipine.
AmlodipineAmlodipine may increase the hypotensive activities of Nicardipine.
AmobarbitalAmobarbital may increase the hypotensive activities of Nicardipine.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Nicardipine.
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Nicardipine.
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Nicardipine.
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Nicardipine.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Nicardipine.
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nicardipine.
AmprenavirThe serum concentration of Nicardipine can be decreased when it is combined with Amprenavir.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Nicardipine.
AmsacrineThe serum concentration of Nicardipine can be increased when it is combined with Amsacrine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Nicardipine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Nicardipine is combined with Amyl Nitrite.
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Nicardipine.
AnagrelideNicardipine may increase the QTc-prolonging activities of Anagrelide.
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Nicardipine.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Nicardipine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Nicardipine.
ApraclonidineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Apraclonidine.
AprepitantThe serum concentration of Nicardipine can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Nicardipine.
AprindineThe metabolism of Aprindine can be decreased when combined with Nicardipine.
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Nicardipine.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Nicardipine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Nicardipine.
AripiprazoleAripiprazole may increase the hypotensive activities of Nicardipine.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Nicardipine.
ArtemetherThe metabolism of Artemether can be decreased when combined with Nicardipine.
AsenapineNicardipine may increase the QTc-prolonging activities of Asenapine.
AstemizoleThe serum concentration of Nicardipine can be increased when it is combined with Astemizole.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Nicardipine.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Nicardipine.
AtenololAtenolol may increase the hypotensive activities of Nicardipine.
AtomoxetineThe metabolism of Nicardipine can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Nicardipine can be increased when it is combined with Atorvastatin.
AtosibanThe risk or severity of adverse effects can be increased when Nicardipine is combined with Atosiban.
Atracurium besylateNicardipine may increase the neuromuscular blocking activities of Atracurium besylate.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Nicardipine.
AzelastineThe serum concentration of Nicardipine can be increased when it is combined with Azelastine.
AzelastineThe metabolism of Azelastine can be decreased when combined with Nicardipine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Nicardipine is combined with Azilsartan medoxomil.
AzithromycinNicardipine may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe serum concentration of Nicardipine can be increased when it is combined with Azithromycin.
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Nicardipine.
BarbitalBarbital may increase the hypotensive activities of Nicardipine.
BedaquilineNicardipine may increase the QTc-prolonging activities of Bedaquiline.
BenazeprilBenazepril may increase the hypotensive activities of Nicardipine.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Nicardipine.
BenmoxinBenmoxin may increase the hypotensive activities of Nicardipine.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Nicardipine.
BenzocaineThe serum concentration of Nicardipine can be increased when it is combined with Benzocaine.
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Nicardipine.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Nicardipine.
BepridilNicardipine may increase the hypotensive activities of Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Nicardipine.
BetaxololBetaxolol may increase the hypotensive activities of Nicardipine.
BethanidineBethanidine may increase the hypotensive activities of Nicardipine.
BexaroteneThe serum concentration of Nicardipine can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Nicardipine.
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Nicardipine.
BimatoprostNicardipine may increase the hypotensive activities of Bimatoprost.
BiperidenThe serum concentration of Nicardipine can be increased when it is combined with Biperiden.
BisoprololBisoprolol may increase the hypotensive activities of Nicardipine.
BoceprevirThe metabolism of Nicardipine can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Nicardipine.
BortezomibThe metabolism of Nicardipine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Nicardipine can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Nicardipine.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Nicardipine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nicardipine.
BretyliumNicardipine may increase the hypotensive activities of Bretylium.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Nicardipine.
BrimonidineNicardipine may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Nicardipine.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Nicardipine.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Nicardipine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Nicardipine.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Nicardipine.
BumetanideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Bumetanide.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Nicardipine.
BupranololNicardipine may increase the hypotensive activities of Bupranolol.
BuprenorphineThe serum concentration of Nicardipine can be increased when it is combined with Buprenorphine.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Nicardipine.
BupropionThe metabolism of Bupropion can be decreased when combined with Nicardipine.
BuspironeThe serum concentration of Nicardipine can be increased when it is combined with Buspirone.
BuspironeThe metabolism of Buspirone can be decreased when combined with Nicardipine.
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Nicardipine.
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Nicardipine.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Nicardipine.
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Nicardipine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Nicardipine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Nicardipine.
CanagliflozinThe risk or severity of adverse effects can be increased when Nicardipine is combined with Canagliflozin.
CandesartanNicardipine may increase the hypotensive activities of Candesartan.
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Nicardipine.
CandoxatrilCandoxatril may increase the hypotensive activities of Nicardipine.
CaptoprilNicardipine may increase the hypotensive activities of Captopril.
CarbamazepineThe serum concentration of Nicardipine can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Nicardipine.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Nicardipine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Nicardipine.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Nicardipine.
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Nicardipine.
CaroxazoneCaroxazone may increase the hypotensive activities of Nicardipine.
CarteololCarteolol may increase the hypotensive activities of Nicardipine.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Nicardipine.
CarvedilolCarvedilol may increase the hypotensive activities of Nicardipine.
CaspofunginThe serum concentration of Nicardipine can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Nicardipine can be decreased when combined with Celecoxib.
CeliprololNicardipine may increase the hypotensive activities of Celiprolol.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Nicardipine.
CeritinibThe serum concentration of Nicardipine can be increased when it is combined with Ceritinib.
CeritinibNicardipine may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Nicardipine.
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Nicardipine.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Nicardipine.
ChloramphenicolThe metabolism of Chloramphenicol can be decreased when combined with Nicardipine.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Nicardipine.
ChloroquineNicardipine may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe serum concentration of Nicardipine can be increased when it is combined with Chloroquine.
ChlorothiazideNicardipine may increase the hypotensive activities of Chlorothiazide.
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Nicardipine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Nicardipine.
ChlorpromazineNicardipine may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpromazineThe serum concentration of Nicardipine can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Nicardipine can be increased when it is combined with Chlorpropamide.
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Nicardipine.
ChlorprothixeneThe serum concentration of Nicardipine can be increased when it is combined with Chlorprothixene.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Nicardipine.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Nicardipine.
CholecalciferolThe metabolism of Nicardipine can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Nicardipine can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Nicardipine can be decreased when it is combined with Cholic Acid.
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Nicardipine.
CilazaprilNicardipine may increase the hypotensive activities of Cilazapril.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Nicardipine.
CimetidineThe serum concentration of Nicardipine can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Nicardipine.
CinacalcetThe metabolism of Nicardipine can be decreased when combined with Cinacalcet.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Nicardipine.
CiprofloxacinNicardipine may increase the QTc-prolonging activities of Ciprofloxacin.
CiprofloxacinThe serum concentration of Nicardipine can be increased when it is combined with Ciprofloxacin.
CisaprideThe metabolism of Cisapride can be decreased when combined with Nicardipine.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Nicardipine.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Nicardipine.
ClarithromycinNicardipine may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe serum concentration of Nicardipine can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Nicardipine can be decreased when combined with Clemastine.
ClevidipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Clevidipine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Nicardipine.
ClobazamThe metabolism of Nicardipine can be decreased when combined with Clobazam.
ClofazimineThe serum concentration of Nicardipine can be increased when it is combined with Clofazimine.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Nicardipine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Nicardipine.
ClomipramineThe serum concentration of Nicardipine can be increased when it is combined with Clomipramine.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Nicardipine.
ClonidineClonidine may increase the hypotensive activities of Nicardipine.
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nicardipine.
ClopidogrelThe metabolism of Nicardipine can be decreased when combined with Clopidogrel.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Nicardipine.
ClotrimazoleThe metabolism of Nicardipine can be decreased when combined with Clotrimazole.
ClozapineNicardipine may increase the QTc-prolonging activities of Clozapine.
ClozapineThe metabolism of Nicardipine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Nicardipine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Nicardipine.
CocaineThe metabolism of Nicardipine can be decreased when combined with Cocaine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Nicardipine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Nicardipine.
ColforsinThe serum concentration of Nicardipine can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Nicardipine can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Nicardipine.
CrizotinibNicardipine may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Nicardipine can be decreased when combined with Crizotinib.
CryptenamineNicardipine may increase the hypotensive activities of Cryptenamine.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Nicardipine.
CyclophosphamideThe serum concentration of Nicardipine can be increased when it is combined with Cyclophosphamide.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Nicardipine.
CyclosporineThe metabolism of Nicardipine can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Nicardipine.
CyclothiazideCyclothiazide may increase the hypotensive activities of Nicardipine.
Cyproterone acetateThe serum concentration of Nicardipine can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Nicardipine.
DabrafenibThe serum concentration of Nicardipine can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Nicardipine.
DaclatasvirThe serum concentration of Nicardipine can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Nicardipine.
DapagliflozinThe risk or severity of adverse effects can be increased when Nicardipine is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Nicardipine.
DapsoneThe metabolism of Dapsone can be decreased when combined with Nicardipine.
DarifenacinThe metabolism of Nicardipine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Nicardipine can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Nicardipine.
DasatinibThe serum concentration of Nicardipine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Nicardipine can be decreased when it is combined with Daunorubicin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Nicardipine.
DebrisoquinNicardipine may increase the hypotensive activities of Debrisoquin.
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Nicardipine.
DeferasiroxThe serum concentration of Nicardipine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Nicardipine can be decreased when combined with Delavirdine.
DeserpidineNicardipine may increase the hypotensive activities of Deserpidine.
DesipramineThe serum concentration of Nicardipine can be increased when it is combined with Desipramine.
DesipramineThe metabolism of Desipramine can be decreased when combined with Nicardipine.
DesloratadineThe serum concentration of Nicardipine can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Nicardipine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Nicardipine.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Nicardipine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Dexmedetomidine.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Nicardipine.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Nicardipine.
DextromethorphanThe serum concentration of Nicardipine can be increased when it is combined with Dextromethorphan.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Nicardipine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Nicardipine.
DiazoxideDiazoxide may increase the hypotensive activities of Nicardipine.
DiclofenacThe serum concentration of Nicardipine can be increased when it is combined with Diclofenac.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Nicardipine.
DiclofenamideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Diclofenamide.
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Nicardipine.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Nicardipine.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Nicardipine.
DigoxinThe serum concentration of Nicardipine can be decreased when it is combined with Digoxin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nicardipine.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Nicardipine.
DihydroergotamineThe metabolism of Nicardipine can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Nicardipine.
DiltiazemDiltiazem may increase the hypotensive activities of Nicardipine.
DinutuximabThe risk or severity of adverse effects can be increased when Nicardipine is combined with Dinutuximab.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Nicardipine.
DipyridamoleThe risk or severity of adverse effects can be increased when Nicardipine is combined with Dipyridamole.
DisopyramideNicardipine may increase the QTc-prolonging activities of Disopyramide.
DisulfiramThe metabolism of Nicardipine can be decreased when combined with Disulfiram.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Nicardipine.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Nicardipine.
DolasetronNicardipine may increase the QTc-prolonging activities of Dolasetron.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Nicardipine.
DonepezilThe metabolism of Donepezil can be decreased when combined with Nicardipine.
DopamineThe metabolism of Dopamine can be decreased when combined with Nicardipine.
DorzolamideNicardipine may increase the hypotensive activities of Dorzolamide.
DoxazosinDoxazosin may increase the hypotensive activities of Nicardipine.
DoxepinThe serum concentration of Nicardipine can be increased when it is combined with Doxepin.
DoxepinThe metabolism of Doxepin can be decreased when combined with Nicardipine.
DoxorubicinThe serum concentration of Nicardipine can be decreased when it is combined with Doxorubicin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Nicardipine.
DoxycyclineThe metabolism of Nicardipine can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Nicardipine.
DronedaroneThe metabolism of Nicardipine can be decreased when combined with Dronedarone.
DroperidolNicardipine may increase the QTc-prolonging activities of Droperidol.
DuloxetineNicardipine may increase the orthostatic hypotensive activities of Duloxetine.
DuloxetineThe metabolism of Nicardipine can be decreased when combined with Duloxetine.
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Nicardipine.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Nicardipine.
EfavirenzThe serum concentration of Nicardipine can be decreased when it is combined with Efavirenz.
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Nicardipine.
EfonidipineNicardipine may increase the hypotensive activities of Efonidipine.
ElbasvirThe serum concentration of Nicardipine can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Nicardipine.
EliglustatThe metabolism of Eliglustat can be decreased when combined with Nicardipine.
EmpagliflozinThe risk or severity of adverse effects can be increased when Nicardipine is combined with Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Nicardipine.
EnalaprilatNicardipine may increase the hypotensive activities of Enalaprilat.
EncainideThe metabolism of Encainide can be decreased when combined with Nicardipine.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Nicardipine.
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Nicardipine.
EnzalutamideThe serum concentration of Nicardipine can be increased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Nicardipine.
EplerenoneThe risk or severity of adverse effects can be increased when Nicardipine is combined with Eplerenone.
EpoprostenolNicardipine may increase the hypotensive activities of Epoprostenol.
EprosartanNicardipine may increase the hypotensive activities of Eprosartan.
ErgonovineThe serum concentration of Nicardipine can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Nicardipine can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Nicardipine.
ErythromycinNicardipine may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Nicardipine can be decreased when combined with Erythromycin.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Nicardipine.
Eslicarbazepine acetateThe serum concentration of Nicardipine can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Nicardipine.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nicardipine.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Nicardipine.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Nicardipine.
EstramustineThe serum concentration of Nicardipine can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Nicardipine can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Nicardipine.
EstroneThe serum concentration of Nicardipine can be decreased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Nicardipine.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Nicardipine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Nicardipine is combined with Etacrynic acid.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Nicardipine.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Nicardipine.
EtodolacThe metabolism of Etodolac can be decreased when combined with Nicardipine.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Nicardipine.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Nicardipine.
EtravirineThe serum concentration of Nicardipine can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Nicardipine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Nicardipine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Nicardipine.
FamotidineThe metabolism of Famotidine can be decreased when combined with Nicardipine.
FelodipineNicardipine may increase the hypotensive activities of Felodipine.
FenoldopamNicardipine may increase the hypotensive activities of Fenoldopam.
FentanylThe serum concentration of Nicardipine can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nicardipine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Nicardipine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Nicardipine.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Nicardipine.
FlecainideNicardipine may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Nicardipine.
FluconazoleThe serum concentration of Nicardipine can be increased when it is combined with Fluconazole.
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Nicardipine.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Nicardipine.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Nicardipine.
FluoxetineThe serum concentration of Nicardipine can be increased when it is combined with Fluoxetine.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Nicardipine.
FlupentixolThe serum concentration of Nicardipine can be increased when it is combined with Flupentixol.
FlupentixolNicardipine may increase the QTc-prolonging activities of Flupentixol.
FluphenazineThe serum concentration of Nicardipine can be increased when it is combined with Fluphenazine.
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Nicardipine.
FlurazepamThe serum concentration of Nicardipine can be increased when it is combined with Flurazepam.
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Nicardipine.
FlutamideThe metabolism of Flutamide can be decreased when combined with Nicardipine.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Nicardipine.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Nicardipine.
FluvoxamineThe metabolism of Nicardipine can be decreased when combined with Fluvoxamine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Nicardipine.
FosamprenavirThe metabolism of Nicardipine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Nicardipine can be increased when it is combined with Fosaprepitant.
FosinoprilFosinopril may increase the hypotensive activities of Nicardipine.
FosphenytoinThe metabolism of Nicardipine can be increased when combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypotensive activities of Nicardipine.
FurosemideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Furosemide.
Fusidic AcidThe serum concentration of Nicardipine can be increased when it is combined with Fusidic Acid.
Gadobenic acidNicardipine may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Nicardipine.
GavestinelThe metabolism of Gavestinel can be decreased when combined with Nicardipine.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Nicardipine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Nicardipine.
GemfibrozilThe metabolism of Nicardipine can be decreased when combined with Gemfibrozil.
GemifloxacinNicardipine may increase the QTc-prolonging activities of Gemifloxacin.
GenisteinThe serum concentration of Nicardipine can be increased when it is combined with Genistein.
GliclazideThe metabolism of Gliclazide can be decreased when combined with Nicardipine.
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Nicardipine.
GlipizideThe metabolism of Glipizide can be decreased when combined with Nicardipine.
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Nicardipine.
GlyburideThe serum concentration of Nicardipine can be increased when it is combined with Glyburide.
GlyburideThe metabolism of Glyburide can be decreased when combined with Nicardipine.
GlycerolThe serum concentration of Nicardipine can be increased when it is combined with Glycerol.
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Nicardipine.
GoserelinNicardipine may increase the QTc-prolonging activities of Goserelin.
Gramicidin DThe serum concentration of Nicardipine can be increased when it is combined with Gramicidin D.
GranisetronNicardipine may increase the QTc-prolonging activities of Granisetron.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Nicardipine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Nicardipine.
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Nicardipine.
GuanabenzNicardipine may increase the hypotensive activities of Guanabenz.
GuanadrelGuanadrel may increase the hypotensive activities of Nicardipine.
GuanethidineNicardipine may increase the hypotensive activities of Guanethidine.
GuanfacineNicardipine may increase the hypotensive activities of Guanfacine.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Nicardipine.
HaloperidolNicardipine may increase the QTc-prolonging activities of Haloperidol.
HaloperidolThe serum concentration of Nicardipine can be increased when it is combined with Haloperidol.
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Nicardipine.
HalothaneThe metabolism of Halothane can be decreased when combined with Nicardipine.
HexamethoniumNicardipine may increase the hypotensive activities of Hexamethonium.
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Nicardipine.
HexobarbitalHexobarbital may increase the hypotensive activities of Nicardipine.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Nicardipine.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Nicardipine.
HydracarbazineHydracarbazine may increase the hypotensive activities of Nicardipine.
HydralazineNicardipine may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideNicardipine may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Nicardipine.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Nicardipine.
HydroflumethiazideNicardipine may increase the hypotensive activities of Hydroflumethiazide.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Nicardipine.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Nicardipine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Nicardipine.
IbutilideNicardipine may increase the QTc-prolonging activities of Ibutilide.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Nicardipine.
IdelalisibThe serum concentration of Nicardipine can be increased when it is combined with Idelalisib.
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Nicardipine.
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Nicardipine.
IloprostIloprost may increase the hypotensive activities of Nicardipine.
ImatinibThe metabolism of Nicardipine can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Nicardipine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Nicardipine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Nicardipine.
IndapamideNicardipine may increase the hypotensive activities of Indapamide.
IndenololNicardipine may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Nicardipine can be decreased when it is combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Nicardipine.
indisulamThe metabolism of indisulam can be decreased when combined with Nicardipine.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Nicardipine.
IndoraminNicardipine may increase the hypotensive activities of Indoramin.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Nicardipine.
IproclozideIproclozide may increase the hypotensive activities of Nicardipine.
IproniazidIproniazid may increase the hypotensive activities of Nicardipine.
IrbesartanNicardipine may increase the hypotensive activities of Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Nicardipine.
IsavuconazoniumThe metabolism of Nicardipine can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Nicardipine.
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Nicardipine.
IsoniazidThe metabolism of Nicardipine can be decreased when combined with Isoniazid.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Nicardipine is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Nicardipine is combined with Isosorbide Mononitrate.
IsoxsuprineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Nicardipine.
ItraconazoleThe serum concentration of Nicardipine can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Nicardipine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Nicardipine.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Nicardipine.
KetamineThe serum concentration of Nicardipine can be increased when it is combined with Ketamine.
KetamineThe metabolism of Ketamine can be decreased when combined with Nicardipine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Nicardipine.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Nicardipine.
KetoconazoleThe serum concentration of Nicardipine can be increased when it is combined with Ketoconazole.
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Nicardipine.
LabetalolLabetalol may increase the hypotensive activities of Nicardipine.
LacidipineNicardipine may increase the hypotensive activities of Lacidipine.
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Nicardipine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Nicardipine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Nicardipine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Nicardipine.
LapatinibThe serum concentration of Nicardipine can be increased when it is combined with Lapatinib.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Nicardipine.
LatanoprostNicardipine may increase the hypotensive activities of Latanoprost.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Nicardipine.
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Nicardipine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Nicardipine.
LenvatinibNicardipine may increase the QTc-prolonging activities of Lenvatinib.
LercanidipineLercanidipine may increase the hypotensive activities of Nicardipine.
LesinuradThe metabolism of Lesinurad can be decreased when combined with Nicardipine.
LeuprolideNicardipine may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Nicardipine.
LevobunololThe risk or severity of adverse effects can be increased when Nicardipine is combined with Levobunolol.
LevodopaNicardipine may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinNicardipine may increase the QTc-prolonging activities of Levofloxacin.
LevofloxacinThe serum concentration of Nicardipine can be increased when it is combined with Levofloxacin.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Nicardipine.
LevothyroxineThe serum concentration of Nicardipine can be decreased when it is combined with Levothyroxine.
LicofeloneThe metabolism of Licofelone can be decreased when combined with Nicardipine.
LidocaineThe serum concentration of Nicardipine can be increased when it is combined with Lidocaine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Nicardipine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Nicardipine.
LiothyronineThe serum concentration of Nicardipine can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Nicardipine can be decreased when it is combined with Liotrix.
LisinoprilNicardipine may increase the hypotensive activities of Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Nicardipine.
LofexidineNicardipine may increase the hypotensive activities of Lofexidine.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Nicardipine.
LomustineThe metabolism of Lomustine can be decreased when combined with Nicardipine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Nicardipine.
LopinavirThe serum concentration of Nicardipine can be increased when it is combined with Lopinavir.
LopinavirNicardipine may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe serum concentration of Nicardipine can be increased when it is combined with Loratadine.
LoratadineThe metabolism of Loratadine can be decreased when combined with Nicardipine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Nicardipine.
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Nicardipine.
LosartanNicardipine may increase the hypotensive activities of Losartan.
LovastatinThe metabolism of Nicardipine can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Nicardipine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Nicardipine can be decreased when it is combined with Lumacaftor.
LumefantrineNicardipine may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Nicardipine can be decreased when combined with Lumefantrine.
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Nicardipine.
MacitentanNicardipine may increase the hypotensive activities of Macitentan.
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium hydroxide.
Magnesium oxideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium salicylate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium Sulfate.
ManidipineNicardipine may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Nicardipine is combined with Mannitol.
MaprotilineThe serum concentration of Nicardipine can be increased when it is combined with Maprotiline.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Nicardipine.
MebanazineMebanazine may increase the hypotensive activities of Nicardipine.
MebendazoleThe serum concentration of Nicardipine can be increased when it is combined with Mebendazole.
MecamylamineNicardipine may increase the hypotensive activities of Mecamylamine.
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Nicardipine.
MefloquineThe serum concentration of Nicardipine can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Nicardipine can be increased when it is combined with Megestrol acetate.
MelatoninThe metabolism of Melatonin can be decreased when combined with Nicardipine.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Nicardipine.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Nicardipine.
MeprobamateThe serum concentration of Nicardipine can be increased when it is combined with Meprobamate.
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Nicardipine.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Nicardipine.
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Nicardipine.
MestranolThe metabolism of Mestranol can be decreased when combined with Nicardipine.
MethadoneNicardipine may increase the QTc-prolonging activities of Methadone.
MethadoneThe serum concentration of Nicardipine can be increased when it is combined with Methadone.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Nicardipine.
MethazolamideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Methazolamide.
MethohexitalMethohexital may increase the hypotensive activities of Nicardipine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Nicardipine.
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Nicardipine.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Nicardipine.
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Nicardipine.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nicardipine.
MethyldopaNicardipine may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Nicardipine.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nicardipine.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Nicardipine.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Nicardipine.
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Nicardipine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Nicardipine.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Nicardipine.
MetipranololNicardipine may increase the hypotensive activities of Metipranolol.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Nicardipine.
MetolazoneMetolazone may increase the hypotensive activities of Nicardipine.
MetoprololMetoprolol may increase the hypotensive activities of Nicardipine.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Nicardipine.
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Nicardipine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Nicardipine.
MianserinThe metabolism of Mianserin can be decreased when combined with Nicardipine.
MibefradilNicardipine may increase the hypotensive activities of Mibefradil.
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Nicardipine.
MiconazoleThe serum concentration of Nicardipine can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Nicardipine can be decreased when it is combined with Midazolam.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Nicardipine.
MifepristoneThe metabolism of Nicardipine can be decreased when combined with Mifepristone.
MifepristoneNicardipine may increase the QTc-prolonging activities of Mifepristone.
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Nicardipine.
MinaprineMinaprine may increase the hypotensive activities of Nicardipine.
MinaprineThe metabolism of Minaprine can be decreased when combined with Nicardipine.
MinoxidilMinoxidil may increase the hypotensive activities of Nicardipine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Nicardipine.
MirabegronThe metabolism of Nicardipine can be decreased when combined with Mirabegron.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Nicardipine.
MitomycinThe serum concentration of Nicardipine can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Nicardipine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Nicardipine can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Nicardipine.
MivacuriumNicardipine may increase the neuromuscular blocking activities of Mivacurium.
MoclobemideMoclobemide may increase the hypotensive activities of Nicardipine.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Nicardipine.
ModafinilThe serum concentration of Nicardipine can be decreased when it is combined with Modafinil.
MoexiprilNicardipine may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Nicardipine.
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Nicardipine.
MontelukastThe metabolism of Montelukast can be decreased when combined with Nicardipine.
MorphineThe serum concentration of Morphine can be increased when it is combined with Nicardipine.
MoxifloxacinNicardipine may increase the QTc-prolonging activities of Moxifloxacin.
MoxonidineNicardipine may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Nicardipine.
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Nicardipine.
NadololNicardipine may increase the hypotensive activities of Nadolol.
NafcillinThe serum concentration of Nicardipine can be decreased when it is combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nicardipine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Nicardipine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Nicardipine.
NaltrexoneThe serum concentration of Nicardipine can be increased when it is combined with Naltrexone.
NaproxenThe metabolism of Naproxen can be decreased when combined with Nicardipine.
NaringeninThe serum concentration of Nicardipine can be increased when it is combined with Naringenin.
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Nicardipine.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Nicardipine.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Nicardipine.
NebivololNebivolol may increase the hypotensive activities of Nicardipine.
NefazodoneThe serum concentration of Nicardipine can be decreased when it is combined with Nefazodone.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Nicardipine.
NelfinavirThe serum concentration of Nicardipine can be decreased when it is combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Nicardipine.
NeostigmineThe serum concentration of Nicardipine can be increased when it is combined with Neostigmine.
NesiritideThe risk or severity of adverse effects can be increased when Nicardipine is combined with Nesiritide.
NetupitantThe serum concentration of Nicardipine can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Nicardipine.
NevirapineThe metabolism of Nicardipine can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Nicardipine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Nicardipine.
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Nicardipine.
NicorandilNicorandil may increase the hypotensive activities of Nicardipine.
NicotineThe metabolism of Nicotine can be decreased when combined with Nicardipine.
NifedipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Nifedipine.
NiguldipineNicardipine may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Nicardipine can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Nicardipine.
NilutamideThe metabolism of Nilutamide can be decreased when combined with Nicardipine.
NilvadipineNicardipine may increase the hypotensive activities of Nilvadipine.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Nicardipine.
NimodipineNimodipine may increase the hypotensive activities of Nicardipine.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Nicardipine.
NisoldipineNisoldipine may increase the hypotensive activities of Nicardipine.
NitrazepamThe serum concentration of Nicardipine can be increased when it is combined with Nitrazepam.
NitrendipineNicardipine may increase the hypotensive activities of Nitrendipine.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Nicardipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Nicardipine is combined with Nitroglycerin.
NitroprussideNicardipine may increase the hypotensive activities of Nitroprusside.
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Nicardipine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Nicardipine.
NorethisteroneThe serum concentration of Nicardipine can be decreased when it is combined with Norethisterone.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Nicardipine.
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Nicardipine.
ObinutuzumabNicardipine may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Nicardipine.
OfloxacinNicardipine may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Nicardipine.
OlaparibThe metabolism of Nicardipine can be decreased when combined with Olaparib.
OlmesartanOlmesartan may increase the hypotensive activities of Nicardipine.
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Nicardipine.
OmapatrilatNicardipine may increase the hypotensive activities of Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Nicardipine.
OmeprazoleThe serum concentration of Nicardipine can be increased when it is combined with Omeprazole.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Nicardipine.
OndansetronNicardipine may increase the QTc-prolonging activities of Ondansetron.
OsimertinibThe serum concentration of Nicardipine can be increased when it is combined with Osimertinib.
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Nicardipine.
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Nicardipine.
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Nicardipine.
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Nicardipine.
OxprenololNicardipine may increase the hypotensive activities of Oxprenolol.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Nicardipine.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Nicardipine.
P-NitrophenolThe serum concentration of Nicardipine can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Nicardipine.
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Nicardipine.
PalbociclibThe serum concentration of Nicardipine can be increased when it is combined with Palbociclib.
PaliperidoneNicardipine may increase the QTc-prolonging activities of Paliperidone.
Palmitic AcidThe serum concentration of Nicardipine can be increased when it is combined with Palmitic Acid.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Nicardipine.
PanobinostatNicardipine may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Nicardipine can be decreased when combined with Panobinostat.
PantoprazoleThe serum concentration of Nicardipine can be increased when it is combined with Pantoprazole.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Nicardipine.
PapaverineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Papaverine.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Nicardipine.
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Nicardipine.
PargylineNicardipine may increase the hypotensive activities of Pargyline.
ParoxetineThe serum concentration of Nicardipine can be increased when it is combined with Paroxetine.
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Nicardipine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Nicardipine.
Peginterferon alfa-2bThe serum concentration of Nicardipine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololNicardipine may increase the hypotensive activities of Penbutolol.
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nicardipine.
PentamidineNicardipine may increase the QTc-prolonging activities of Pentamidine.
PentobarbitalPentobarbital may increase the hypotensive activities of Nicardipine.
PentobarbitalThe metabolism of Pentobarbital can be decreased when combined with Nicardipine.
PentoliniumNicardipine may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Nicardipine.
PerflutrenNicardipine may increase the QTc-prolonging activities of Perflutren.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Nicardipine.
PerindoprilNicardipine may increase the hypotensive activities of Perindopril.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Nicardipine.
PethidineThe metabolism of Pethidine can be decreased when combined with Nicardipine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Nicardipine.
PhenelzinePhenelzine may increase the hypotensive activities of Nicardipine.
PhenforminThe metabolism of Phenformin can be decreased when combined with Nicardipine.
PheniprazinePheniprazine may increase the hypotensive activities of Nicardipine.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Nicardipine.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Nicardipine.
PhenoxybenzamineNicardipine may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Nicardipine.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Nicardipine.
PhentolamineNicardipine may increase the hypotensive activities of Phentolamine.
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Nicardipine.
PhenytoinThe metabolism of Nicardipine can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Nicardipine.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Nicardipine.
PinacidilNicardipine may increase the hypotensive activities of Pinacidil.
PindololNicardipine may increase the hypotensive activities of Pindolol.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Nicardipine.
PiperazineThe metabolism of Piperazine can be decreased when combined with Nicardipine.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Nicardipine.
PirlindolePirlindole may increase the hypotensive activities of Nicardipine.
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Nicardipine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Nicardipine.
PivhydrazinePivhydrazine may increase the hypotensive activities of Nicardipine.
Platelet Activating FactorThe serum concentration of Nicardipine can be decreased when it is combined with Platelet Activating Factor.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Nicardipine.
PolythiazideNicardipine may increase the hypotensive activities of Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Nicardipine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Nicardipine.
PosaconazoleThe serum concentration of Nicardipine can be increased when it is combined with Posaconazole.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Nicardipine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Nicardipine.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Nicardipine.
PrazosinPrazosin may increase the hypotensive activities of Nicardipine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Nicardipine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Nicardipine.
PrimaquineNicardipine may increase the QTc-prolonging activities of Primaquine.
PrimidonePrimidone may increase the hypotensive activities of Nicardipine.
PrimidoneThe metabolism of Primidone can be decreased when combined with Nicardipine.
ProbenecidThe serum concentration of Nicardipine can be increased when it is combined with Probenecid.
ProcainamideThe metabolism of Procainamide can be decreased when combined with Nicardipine.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Nicardipine.
ProgesteroneThe serum concentration of Nicardipine can be decreased when it is combined with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Nicardipine.
ProguanilThe metabolism of Proguanil can be decreased when combined with Nicardipine.
PromazineNicardipine may increase the QTc-prolonging activities of Promazine.
PromazineThe metabolism of Nicardipine can be decreased when combined with Promazine.
PromethazineThe serum concentration of Nicardipine can be increased when it is combined with Promethazine.
PromethazineThe metabolism of Promethazine can be decreased when combined with Nicardipine.
PropafenoneThe serum concentration of Nicardipine can be increased when it is combined with Propafenone.
PropafenoneNicardipine may increase the QTc-prolonging activities of Propafenone.
PropofolThe metabolism of Propofol can be decreased when combined with Nicardipine.
PropranololPropranolol may increase the hypotensive activities of Nicardipine.
ProtriptylineThe serum concentration of Nicardipine can be increased when it is combined with Protriptyline.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Nicardipine.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Nicardipine.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Nicardipine.
QuazepamThe metabolism of Quazepam can be decreased when combined with Nicardipine.
QuercetinThe serum concentration of Nicardipine can be increased when it is combined with Quercetin.
QuetiapineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Quetiapine.
QuinacrineThe serum concentration of Nicardipine can be increased when it is combined with Quinacrine.
QuinaprilNicardipine may increase the hypotensive activities of Quinapril.
QuinidineThe serum concentration of Nicardipine can be increased when it is combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Nicardipine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Nicardipine.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Nicardipine.
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Nicardipine.
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Nicardipine.
RamiprilRamipril may increase the hypotensive activities of Nicardipine.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Nicardipine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Nicardipine.
RapacuroniumNicardipine may increase the neuromuscular blocking activities of Rapacuronium.
RasagilineRasagiline may increase the hypotensive activities of Nicardipine.
ReboxetineThe serum concentration of Nicardipine can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Nicardipine can be increased when it is combined with Regorafenib.
RemikirenRemikiren may increase the hypotensive activities of Nicardipine.
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Nicardipine.
repinotanThe metabolism of repinotan can be decreased when combined with Nicardipine.
RescinnamineNicardipine may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Nicardipine.
RifabutinThe metabolism of Nicardipine can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Nicardipine can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Nicardipine.
RifapentineThe metabolism of Nicardipine can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Nicardipine.
RilpivirineThe serum concentration of Nicardipine can be increased when it is combined with Rilpivirine.
RiociguatNicardipine may increase the hypotensive activities of Riociguat.
RisperidoneNicardipine may increase the hypotensive activities of Risperidone.
RitonavirThe serum concentration of Nicardipine can be decreased when it is combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Nicardipine.
RituximabNicardipine may increase the hypotensive activities of Rituximab.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Nicardipine.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Nicardipine.
RolapitantThe serum concentration of Nicardipine can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Nicardipine.
RopiniroleThe metabolism of Nicardipine can be decreased when combined with Ropinirole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Nicardipine.
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Nicardipine.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Nicardipine.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Nicardipine.
SafrazineSafrazine may increase the hypotensive activities of Nicardipine.
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Nicardipine.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nicardipine.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Nicardipine.
SaprisartanNicardipine may increase the hypotensive activities of Saprisartan.
SaquinavirNicardipine may increase the QTc-prolonging activities of Saquinavir.
SaquinavirThe serum concentration of Nicardipine can be decreased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Nicardipine.
ScopolamineThe serum concentration of Nicardipine can be increased when it is combined with Scopolamine.
SecobarbitalSecobarbital may increase the hypotensive activities of Nicardipine.
SelegilineSelegiline may increase the hypotensive activities of Nicardipine.
SelegilineThe metabolism of Selegiline can be decreased when combined with Nicardipine.
SelexipagNicardipine may increase the hypotensive activities of Selexipag.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Nicardipine.
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Nicardipine.
SertindoleThe metabolism of Sertindole can be decreased when combined with Nicardipine.
SertralineThe serum concentration of Nicardipine can be increased when it is combined with Sertraline.
SertralineThe metabolism of Sertraline can be decreased when combined with Nicardipine.
SildenafilSildenafil may increase the antihypertensive activities of Nicardipine.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Nicardipine.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Nicardipine.
SilodosinSilodosin may increase the hypotensive activities of Nicardipine.
SiltuximabThe serum concentration of Nicardipine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Nicardipine can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Nicardipine can be increased when it is combined with Simvastatin.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Nicardipine.
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Nicardipine.
SirolimusThe serum concentration of Nicardipine can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Nicardipine.
SitaxentanNicardipine may increase the hypotensive activities of Sitaxentan.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Nicardipine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Nicardipine.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Nicardipine.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Nicardipine.
SparteineThe metabolism of Sparteine can be decreased when combined with Nicardipine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Nicardipine.
SpiraprilNicardipine may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Nicardipine.
St. John's WortThe serum concentration of Nicardipine can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Nicardipine can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Nicardipine can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Nicardipine can be decreased when it is combined with Streptozocin.
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Nicardipine.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Nicardipine.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Nicardipine.
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Nicardipine.
SulfinpyrazoneThe serum concentration of Nicardipine can be increased when it is combined with Sulfinpyrazone.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Nicardipine.
SulfisoxazoleNicardipine may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Nicardipine can be decreased when combined with Sulfisoxazole.
SumatriptanThe serum concentration of Nicardipine can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Nicardipine can be increased when it is combined with Sunitinib.
SuprofenThe metabolism of Suprofen can be decreased when combined with Nicardipine.
TacrineThe serum concentration of Nicardipine can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Nicardipine can be decreased when it is combined with Tacrolimus.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Nicardipine.
TadalafilTadalafil may increase the antihypertensive activities of Nicardipine.
TamoxifenThe serum concentration of Nicardipine can be decreased when it is combined with Tamoxifen.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Nicardipine.
TamsulosinTamsulosin may increase the hypotensive activities of Nicardipine.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Nicardipine.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Nicardipine.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Nicardipine.
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Nicardipine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Nicardipine.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Nicardipine.
TelaprevirThe metabolism of Nicardipine can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Nicardipine.
TelavancinNicardipine may increase the QTc-prolonging activities of Telavancin.
TelithromycinNicardipine may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Nicardipine can be decreased when combined with Telithromycin.
TelmisartanNicardipine may increase the hypotensive activities of Telmisartan.
TemazepamThe metabolism of Temazepam can be decreased when combined with Nicardipine.
TemocaprilNicardipine may increase the hypotensive activities of Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Nicardipine.
TeniposideThe metabolism of Teniposide can be decreased when combined with Nicardipine.
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Nicardipine.
TerazosinTerazosin may increase the hypotensive activities of Nicardipine.
TerazosinThe risk or severity of adverse effects can be increased when Nicardipine is combined with Terazosin.
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Nicardipine.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Nicardipine.
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Nicardipine.
TerfenadineThe serum concentration of Nicardipine can be increased when it is combined with Terfenadine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Nicardipine.
TeriflunomideThe metabolism of Nicardipine can be decreased when combined with Teriflunomide.
TerlipressinNicardipine may increase the hypotensive activities of Terlipressin.
TesmilifeneThe serum concentration of Nicardipine can be decreased when it is combined with Tesmilifene.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Nicardipine.
TestosteroneThe serum concentration of Nicardipine can be increased when it is combined with Testosterone.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Nicardipine.
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Nicardipine.
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Nicardipine.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Nicardipine.
ThiamylalThiamylal may increase the hypotensive activities of Nicardipine.
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Nicardipine.
ThiopentalThiopental may increase the hypotensive activities of Nicardipine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Nicardipine.
ThioridazineThe metabolism of Nicardipine can be decreased when combined with Thioridazine.
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Nicardipine.
TiboloneNicardipine may increase the hypotensive activities of Tibolone.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Nicardipine.
TiclopidineThe metabolism of Nicardipine can be decreased when combined with Ticlopidine.
TicrynafenNicardipine may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Nicardipine.
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Nicardipine.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Nicardipine.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Nicardipine.
TizanidineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Tizanidine.
TocilizumabThe serum concentration of Nicardipine can be decreased when it is combined with Tocilizumab.
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Nicardipine.
TolazolineNicardipine may increase the hypotensive activities of Tolazoline.
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Nicardipine.
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Nicardipine.
ToloxatoneToloxatone may increase the hypotensive activities of Nicardipine.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Nicardipine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Nicardipine.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Nicardipine.
TorasemideTorasemide may increase the hypotensive activities of Nicardipine.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Nicardipine.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Nicardipine.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Nicardipine.
TrandolaprilTrandolapril may increase the hypotensive activities of Nicardipine.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nicardipine.
TranylcypromineTranylcypromine may increase the hypotensive activities of Nicardipine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Nicardipine.
TravoprostTravoprost may increase the hypotensive activities of Nicardipine.
TrazodoneThe serum concentration of Nicardipine can be decreased when it is combined with Trazodone.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Nicardipine.
TreprostinilTreprostinil may increase the hypotensive activities of Nicardipine.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Nicardipine.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nicardipine.
TrichlormethiazideNicardipine may increase the hypotensive activities of Trichlormethiazide.
TrifluoperazineThe serum concentration of Nicardipine can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Nicardipine can be increased when it is combined with Triflupromazine.
TrimazosinNicardipine may increase the hypotensive activities of Trimazosin.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Nicardipine.
TrimethaphanNicardipine may increase the hypotensive activities of Trimethaphan.
TrimethoprimThe serum concentration of Nicardipine can be decreased when it is combined with Trimethoprim.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Nicardipine.
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Nicardipine.
TrimipramineThe serum concentration of Nicardipine can be increased when it is combined with Trimipramine.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Nicardipine.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Nicardipine.
TroleandomycinThe serum concentration of Nicardipine can be increased when it is combined with Troleandomycin.
UdenafilUdenafil may increase the antihypertensive activities of Nicardipine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Nicardipine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Nicardipine.
UnoprostoneNicardipine may increase the hypotensive activities of Unoprostone.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Nicardipine.
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Nicardipine.
ValsartanValsartan may increase the hypotensive activities of Nicardipine.
VandetanibNicardipine may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the antihypertensive activities of Nicardipine.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Nicardipine.
VemurafenibNicardipine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Nicardipine can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Nicardipine.
VerapamilThe risk or severity of adverse effects can be increased when Nicardipine is combined with Verapamil.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Nicardipine.
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Nicardipine.
VinblastineThe serum concentration of Nicardipine can be decreased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Nicardipine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Nicardipine.
VincristineThe serum concentration of Nicardipine can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Nicardipine can be increased when it is combined with Vinorelbine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Nicardipine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Nicardipine.
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Nicardipine.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Nicardipine.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Nicardipine.
WarfarinThe metabolism of Warfarin can be decreased when combined with Nicardipine.
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Nicardipine.
XylometazolineNicardipine may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Nicardipine.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Nicardipine.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Nicardipine.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Nicardipine.
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Nicardipine.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Nicardipine.
ZileutonThe metabolism of Zileuton can be decreased when combined with Nicardipine.
ZimelidineThe serum concentration of Nicardipine can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Nicardipine can be decreased when combined with Ziprasidone.
ZiprasidoneNicardipine may increase the QTc-prolonging activities of Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Nicardipine.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Nicardipine.
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Nicardipine.
Food Interactions
  • Grapefruit and grapefruit juice should be avoided throughout treatment. Grapefruit can increase serum levels of this product.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1C
Uniprot ID:
Q13936
Molecular Weight:
248974.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB2
Uniprot ID:
Q08289
Molecular Weight:
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1D
Uniprot ID:
Q01668
Molecular Weight:
245138.75 Da
References
  1. Bell DC, Butcher AJ, Berrow NS, Page KM, Brust PF, Nesterova A, Stauderman KA, Seabrook GR, Nurnberg B, Dolphin AC: Biophysical properties, pharmacology, and modulation of human, neuronal L-type (alpha(1D), Ca(V)1.3) voltage-dependent calcium currents. J Neurophysiol. 2001 Feb;85(2):816-27. [PubMed:11160515 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-contraction coupling (By similarity).
Gene Name:
CACNA2D1
Uniprot ID:
P54289
Molecular Weight:
124566.93 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a higher affinity for cGMP than for cAMP.
Gene Name:
PDE1A
Uniprot ID:
P54750
Molecular Weight:
61251.38 Da
References
  1. Sharma RK, Wang JH, Wu Z: Mechanisms of inhibition of calmodulin-stimulated cyclic nucleotide phosphodiesterase by dihydropyridine calcium antagonists. J Neurochem. 1997 Aug;69(2):845-50. [PubMed:9231746 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a preference for cGMP as a substrate.
Gene Name:
PDE1B
Uniprot ID:
Q01064
Molecular Weight:
61379.235 Da
References
  1. Sharma RK, Wang JH, Wu Z: Mechanisms of inhibition of calmodulin-stimulated cyclic nucleotide phosphodiesterase by dihydropyridine calcium antagonists. J Neurochem. 1997 Aug;69(2):845-50. [PubMed:9231746 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80. [PubMed:2981533 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80. [PubMed:2981533 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80. [PubMed:2981533 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80. [PubMed:2981533 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80. [PubMed:2981533 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80. [PubMed:2981533 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80. [PubMed:2981533 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80. [PubMed:2981533 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Titin binding
Specific Function:
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis.
Gene Name:
CALM1
Uniprot ID:
P62158
Molecular Weight:
16837.47 Da
References
  1. Thayer SA, Fairhurst AS: The interaction of dihydropyridine calcium channel blockers with calmodulin and calmodulin inhibitors. Mol Pharmacol. 1983 Jul;24(1):6-9. [PubMed:6865927 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Katoh M, Nakajima M, Yamazaki H, Yokoi T: Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Pharm Res. 2000 Oct;17(10):1189-97. [PubMed:11145223 ]
  2. Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE: Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm Res. 2000 Dec;17(12):1456-60. [PubMed:11303953 ]
  3. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
  4. Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K: Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci. 2002 Aug;16(3):159-65. [PubMed:12128170 ]
  5. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  6. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465 ]
  7. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 28, 2016 02:25